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TNM stage T1-2, N0, M0 with PSA 10 ng/Ml and Gleason
score 7, and localized PC as TNM stage T2, N0, M0. Next, we
developed models for estimating the number of men in these two
groups for the US, European Union (EU) and Japan. Finally, we
populated these models with information derived from a com-
prehensive review of incidence and staging estimates from
English-language literature and publicly available demographic
and registry data. RESULTS: We identiﬁed over 100 relevant
abstracts that yielded 67 manuscripts for review, 15 of which
provided data for the model. The estimated number of newly
diagnosed men with early-stage PC was 120,000 (US), 140,000
(EU), and 4,300 (Japan). The corresponding incidence rates per
100,000 males were 85, 58 and 7, respectively. The estimated
number (incidence) of newly diagnosed men with localized PC
was 89,000 (63), 71,000 (29) and 10,000 (15) in the US, EU and
Japan, respectively. CONCLUSION: The number of men at risk
for over- or under-utilization of radical prostatectomy due to
inadequate diagnostic information is substantial and varies
widely by country.
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OBJECTIVES: Although the use of various generic drugs is
becoming national policy in Japan to reduce health care costs,
many physicians tend to be reluctant to prescribe generic drugs,
especially in cancer therapy. The purpose of this study was to
investigate the attitude of physicians involved in breast cancer
treatment towards the prescription and use of generic anti-cancer
drugs in Japan. METHODS: Questionnaires were sent to 180
physicians who had registered with the multi-center trial group
for breast cancer therapy in Japan (CSPOR). RESULTS: The
respondents were 73 (response rate: 41%), their average age was
45.1, and their years of experience with breast cancer treatment
averaged 14.1. Their basic attitude concerning generic drugs was
“I would prescribe them if the patient asks” among 64%, “I am
actively prescribing them” among 21%, and “I would prefer not
to prescribe them, if possible” among 14% of respondents. 32%
of physicians had no experience with the use of generic anti-
cancer drugs. The reasons why they did not use them were
“constraints of the ordering system” (49%), “my own policy”
(21%), and “institutional policy” (13%). The policy for the
selection of brand or generic anti-cancer drugs was “based on
patients’ preference” (44%), “commitment to generic drugs”
(14%), “decide by the name of the drug company” (24%), and
“follow the institutional policy” (24%). As to the selection of
generic drugs, seventy-nine percent of respondents trusted
generic drugs manufactured by a brand name company over
those made by a specialized producer of generic drugs. CON-
CLUSION: A little less than 70 percent of breast cancer thera-
pists had prescribed generic anti-cancer drugs. It became clear
that the selection policy for brand or generic anti-cancer drugs
was based on patient preferences.
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OBJECTIVES: During the last decades, breast cancer screening
programs have considerably increased in terms of number and
improved in terms of clinical and technical standards. From an
HTA perspective, clinical and economic issues are only two of
several important aspects concerning breast cancer screening
programs. The objective of research is to investigate to what
extend societal and ethical aspects as well as the perspective of
equal access for different groups of the population are addressed
in breast cancer screening evaluation initiatives. METHODS:
Systematic literature research; comparative analysis of societal,
ethical and access aspects on the basis of several practical
examples of screening programs in different countries and of
theoretic scientiﬁc literature; evaluating structures of program-
organisation along pre-deﬁned indicators. RESULTS: In several
countries breast cancer screening programs are also evaluated
according to others than conventional indicators. These indica-
tors do express attendance rates according to different social
groups, and thus may explain differences in epidemiological out-
comes of screening programs. CONCLUSION: Basic epidemio-
logical indicators of the success of breast cancer screening such as
prevalence can strongly vary depending on non-clinical and non-
economic characteristics of screening programs. These societal,
ethnic, ethical or equity aspects are primarily to be addressed via
the organisational part of the programs. This is one reason why
quality assurance in breast cancer screening should not only be
strictly executed but also be improved in terms of a quality
management.
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OBJECTIVES: Describe the treatment patterns of GBM patients
in Germany. METHODS: Between January and February 2006,
retrospective case histories of 50 adult GBM patients no longer
receiving active treatment were provided by 10 physicians from
10 German institutions. RESULTS: Seventy percent of patients
were diagnosed in 2004–5. 60% of patients were male; 58%
were >50 years old. At diagnosis, patients were classed as fully
active (26% with no neurological symptoms; 42% with minor
symptoms); 22% were fully active with assistance with moderate
symptoms, 6% were less than fully active with moderate symp-
toms and 4% were disabled with severe symptoms. 49 patients
had their initial therapy recorded; all underwent surgery. Subse-
quently, 39% underwent chemoradiation, 39% radiotherapy,
and 14% chemotherapy. Of those undergoing chemoradiation,
94% received temozolomide. Of those undergoing radiotherapy,
53% subsequently received chemotherapy before relapse; 90%
received temozolomide either as a single-agent or in combination
with doxorubicin. Disease recurrence was documented for 36 of
50 patients, of which 13% had no neurological symptoms, 41%
had minor symptoms, 28% had moderate symptoms and were
fully active with assistance, and 19% had moderate symptoms
and were less than fully active. Forty-two percent (15/36) were
treated with chemotherapy initially for their recurrence; patients
received a variety of single-agent or combination regimens of
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